番茄社区app

Prices slashed by as much as 79%

More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing

Poor air quality adds significantly to risk from genetic susceptibility factors

Previous exposure to biologics, higher BMI, smoking all negatively linked to response

Early phase III data cement case for novel IL-17A inhibitor

Studies may explain some cases of rare opportunistic infections

EULAR provides easy-to-understand algorithm

High response rates out to 52 weeks with IL-23 inhibitor, correlating with eradication of T cells

Noninferiority achieved across all skin subtypes

Also in TTHealthWatch: managing gout with uric acid levels

At least 75% improvement in up to 79% of patients at 16 weeks, 90% improvement in 60%

More biomarker research is needed, but new study is a good start

Richard Warren explains the factors he considers and what his "go-to" treatment is

Experts discuss importance of both physician- and patient-reported domains